Item:Q190706: Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Redirected to Q3698691)
Tag: New redirect
 
(17 intermediate revisions by 2 users not shown)
redirectredirect
 
Q3698691
label / frlabel / fr
12012 - MIMEDI
label / enlabel / en
12012 — MIMEDI
description / endescription / en
Project in France financed by DG Regio
description / frdescription / fr
Projet en France financé par DG Regio
Property / French Kohesio ID
10341
 
Property / French Kohesio ID: 10341 / rank
Normal rank
 
Property / instance of
 
Property / instance of: Kohesio project / rank
Normal rank
 
Property / country
 
Property / country: France / rank
Normal rank
 
Property / EU contribution
10,211,026.83 Euro
Amount10,211,026.83 Euro
UnitEuro
 
Property / EU contribution: 10,211,026.83 Euro / rank
Normal rank
 
Property / budget
13,614,711.32 Euro
Amount13,614,711.32 Euro
UnitEuro
 
Property / budget: 13,614,711.32 Euro / rank
Normal rank
 
Property / postal code
25030
 
Property / postal code: 25030 / rank
Normal rank
 
Property / start time
1 December 2017
Timestamp+2017-12-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / start time: 1 December 2017 / rank
Normal rank
 
Property / end time
30 November 2021
Timestamp+2021-11-30T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / end time: 30 November 2021 / rank
Normal rank
 
Property / beneficiary name (string)
Université de Franche-Comté
 
Property / beneficiary name (string): Université de Franche-Comté / rank
Normal rank
 
Property / summary
Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
 
Property / summary: Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French) / rank
Normal rank
 
Property / summary
Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English)
 
Property / summary: Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English) / rank
Normal rank
 
Property / intervention field
 
Property / intervention field: Technology transfer and university-enterprise cooperation primarily benefiting SMEs / rank
Normal rank
 
Property / coordinate location
47°14'23.03"N, 6°0'44.14"E
Latitude47.239733666667
Longitude6.0122559333333
Precision1.0E-5
Globehttp://www.wikidata.org/entity/Q2
 
Property / coordinate location: 47°14'23.03"N, 6°0'44.14"E / rank
Normal rank
 
Property / financed by
 
Property / financed by: European Union / rank
Normal rank
 
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
Normal rank
 
Property / programme
 
Property / programme: Franche-Comté et Jura - ERDF/ESF / rank
Normal rank
 
Property / co-financing rate
75.0 percent
Amount75.0 percent
Unitpercent
 
Property / co-financing rate: 75.0 percent / rank
Normal rank
 
Property / beneficiary
Q2537920 (Deleted Item)
 
Property / beneficiary: Q2537920 (Deleted Item) / rank
Normal rank
 
Property / ID used by InfoRegio
4607
 
Property / ID used by InfoRegio: 4607 / rank
Normal rank
 
Property / info Regio url
 
Property / info Regio url: https://ec.europa.eu/regional_policy/en/projects/europe/mimedi-optimiser-la-fabrication-de-medicaments-innovants-en-evitant-le-recours-aux-salles-blanches / rank
Normal rank
 
Property / image url
 
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / rank
Normal rank
 
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier
summary: Device for biological element sorting by acoustophoresis. (English)
 
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier
copyright: Quarroz – FEMTO, Univ-Franche-Comte 2018
 
Property / fund
 
Property / fund: European Regional Development Fund / rank
Normal rank
 

Latest revision as of 13:44, 16 May 2022

Redirect to: